Literature DB >> 21733661

Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases.

Y Gillet1, O Dumitrescu, A Tristan, O Dauwalder, E Javouhey, D Floret, F Vandenesch, J Etienne, G Lina.   

Abstract

Panton-Valentine leukocidin (PVL)-producing Staphylococcus aureus is associated with a broad spectrum of diseases, ranging from common uncomplicated soft tissue infections to severe diseases such as complicated soft tissue infections, extensive bone and joint infections, and necrotising pneumonia. Specialised management of infection based on the presence of PVL may not be required for mild infections, whereas it could be lifesaving in other settings. Moreover, most severe PVL diseases are recently identified entities and a 'gold standard' treatment from comparatives studies of different therapeutic options is lacking. Thus, recommendations are based on expert opinions, which are elaborated based on theory, in vitro data and analogies with other toxin-mediated diseases. In this review, we consider the potential need for specialised PVL-based management and, if required, which tools should be used to achieve optimal management.
Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733661     DOI: 10.1016/j.ijantimicag.2011.05.003

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  22 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Panton-Valentine leukocidin-positive staphylococcus aureus necrotising pneumonia complicating pandemic A(H1N1) influenza infection.

Authors:  Florent Valour; Jean-Christophe Richard; Christian Chidiac; Tristan Ferry
Journal:  BMJ Case Rep       Date:  2013-08-23

3.  Treatment of severe MRSA infections: current practice and further development.

Authors:  José-Artur Paiva; Philippe Eggimann
Journal:  Intensive Care Med       Date:  2016-10-04       Impact factor: 17.440

4.  Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports.

Authors:  Lukas Kreienbuehl; Emmanuel Charbonney; Philippe Eggimann
Journal:  Ann Intensive Care       Date:  2011-12-22       Impact factor: 6.925

5.  Survey of Staphylococcus aureus in a general pediatric population and focus on isolates with three clinically relevant toxin-encoding genes.

Authors:  Anne Filleron; Sarah Beauregard-Birba; Thibault Mura; Fabien Aujoulat; Anne Laure Michon; Michel Rodière; Tu Anh Tran; Eric Jeziorski; Hélène Marchandin
Journal:  World J Pediatr       Date:  2018-02-13       Impact factor: 2.764

Review 6.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

7.  Rapid Bacterial Identification, Resistance, Virulence and Type Profiling using Selected Reaction Monitoring Mass Spectrometry.

Authors:  Yannick Charretier; Olivier Dauwalder; Christine Franceschi; Elodie Degout-Charmette; Gilles Zambardi; Tiphaine Cecchini; Chloe Bardet; Xavier Lacoux; Philippe Dufour; Laurent Veron; Hervé Rostaing; Veronique Lanet; Tanguy Fortin; Corinne Beaulieu; Nadine Perrot; Dominique Dechaume; Sylvie Pons; Victoria Girard; Arnaud Salvador; Géraldine Durand; Frédéric Mallard; Alain Theretz; Patrick Broyer; Sonia Chatellier; Gaspard Gervasi; Marc Van Nuenen; Carolyn Ann Roitsch; Alex Van Belkum; Jérôme Lemoine; François Vandenesch; Jean-Philippe Charrier
Journal:  Sci Rep       Date:  2015-09-09       Impact factor: 4.379

8.  Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureus Panton-Valentine leukocidin for diagnostic and therapeutic applications.

Authors:  Charles Emeka Okolie; Alan Cockayne; Christopher Penfold; Richard James
Journal:  BMC Biotechnol       Date:  2013-11-19       Impact factor: 2.563

9.  Skin infections due to Panton-Valentine leukocidin (PVL)-producing S. aureus-Cost effectiveness of outpatient treatment.

Authors:  Marc-Nicolas Rentinck; Renate Krüger; Pia-Alice Hoppe; Daniel Humme; Michaela Niebank; Anna Pokrywka; Miriam Stegemann; Axel Kola; Leif Gunnar Hanitsch; Rasmus Leistner
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

Review 10.  Panton-valentine leukocidin Staphylococcus aureus severe infection in an infant: a case report and a review of the literature.

Authors:  Massimo Luca Castellazzi; Samantha Bosis; Irene Borzani; Claudia Tagliabue; Raffaella Pinzani; Paola Marchisio; Giada Maria di Pietro
Journal:  Ital J Pediatr       Date:  2021-07-17       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.